Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – FitzGerald Website

David J. FitzGerald, Ph.D.

Selected Publications

1)  Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, Wayne AS, Mackall CL, Orentas RJ.
Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.
Blood. 121: 1165-74, 2013.
2)  Liu XF, Fitzgerald DJ, Pastan I.
The insulin receptor negatively regulates the action of pseudomonas toxin-based immunotoxins and native pseudomonas toxin.
Cancer Res. 73: 2281-8, 2013.
3)  Mattoo A, Fitzgerald DJ.
Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant Small Cell Lung Cancer cell lines.
Int J Cancer. [Epub ahead of print], 2012.
4)  Wei H, Xiang L, Wayne AS, Chertov O, Fitzgerald DJ, Bera TK, Pastan I.
Immunotoxin resistance via reversible methylation of the DPH4 promoter is a unique survival strategy.
Proc. Natl. Acad. Sci. U.S.A. 109: 6898-903, 2012.
5)  Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, Fitzgerald DJ, Lechleider R, Pastan I.
Phase I Trial of Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox (CAT-8015 or HA22) in Patients With Hairy Cell Leukemia.
J. Clin. Oncol. 30: 1822-8, 2012.
6)  Fitzgerald DJ, Moskatel E, Ben-Josef G, Traini R, Tendler T, Sharma A, Antignani A, Mussai F, Wayne A, Kreitman RJ, Pastan I.
Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.
Leuk. Lymphoma. 52 Suppl 2: 79-81, 2011.
7)  Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R.
Immunotoxins with decreased immunogenicity and improved activity.
Leuk. Lymphoma. 52 Suppl 2: 87-90, 2011.
8)  Kreitman RJ, Arons E, Stetler-Stevenson M, Fitzgerald DJ, Wilson WH, Pastan I.
Recombinant immunotoxins and other therapies for relapsed/refractory hairy cell leukemia.
Leuk. Lymphoma. 52 Suppl 2: 82-6, 2011.
9)  FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I.
Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates.
Cancer Res. 71: 6300-9, 2011.
10)  Traini R, Ben-Josef G, Pastrana DV, Moskatel E, Sharma AK, Antignani A, Fitzgerald DJ.
ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol.
Mol. Cancer Ther. 9: 2007-15, 2010.
Click Here to View Expanded Bibliography.

This page was last updated on 4/9/2013.